Home - Zai Lab
Jan 10, 2025 · Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for oncology, immunology, neuroscience, and infectious diseases to patients in China and around the world.
Zai Lab Receives Orphan Drug Designation from the U.S. FDA
3 days ago · Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience ...
About Zai Lab
Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company based in China and the U.S. We are focused on bringing best-in-class and first-in-class medicines for oncology, immunology, neuroscience, and infectious diseases to patients in greater China and around the world.
Zai Lab Limited (ZLAB) - Yahoo Finance
Find the latest Zai Lab Limited (ZLAB) stock quote, history, news and other vital information to help you with your stock trading and investing.
Our R&D - Zai Lab
Abbreviations: Second line+ (2L+), extensive-stage small cell lung cancer (ES-SCLC), Recurrent or metastatic (r/m), tissue factor (TF), hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), lupus nephritis (LN), atopic dermatitis (AD).
Zai Lab Announces Positive Topline Results for TIVDAK in the …
Jan 15, 2025 · SHANGHAI & CAMBRIDGE, Mass., January 15, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 ...
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for …
3 days ago · About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology ...
Zai Lab Presents Interim Overall Survival Data for ... - Zai Lab …
In September 2020, Zai Lab announced the detailed positive results from the NORA study, showing ZEJULA demonstrated significant progression-free survival (PFS) benefit for patients in China with platinum-sensitive, recurrent ovarian cancer, regardless of biomarker status. In NORA, niraparib treatment resulted in a 68% reduction in the risk of ...
Vertex and Zai Lab Announce Strategic Agreement to Develop …
Jan 19, 2025 · About Zai Lab. Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering ...
Zai Lab Receives Orphan Drug Designation from the U.S
3 days ago · About Zai Lab. Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering ...